Skip to main content
. 2005 May 27;43(1):12–17. doi: 10.1136/jmg.2005.032193

Table 2 Genotype relative risks needed to achieve power of 0.80 and 0.95 in family based tests of the association of psoriasis with RAPTOR and RUNX1 SNPs*.

Locus† Genetic model GRR2/GRR1 for power of 0.80 GRR2/GRR1 for power of 0.95
TDT PDT FBAT TDT PDT FBAT
RUNX1 Dominant 1.69/1.69 1.61/1.61 1.52/1.52 2.00/2.00 1.92/1.92 1.75/1.75
Additive 1.69/1.35 1.62/1.31 1.53/1.27 1.96/1.48 1.87/1.44 1.73/1.37
Multiplicative 1.69/1.30 1.62/1.27 1.52/1.23 1.96/1.40 1.86/1.36 1.72/1.31
Recessive 1.69/– 1.63/– 1.53/– 1.93/– 1.84/– 1.70/–
RAPTOR Dominant –‡ –‡ –‡ –‡ –‡ –‡
Additive 2.09/1.54 1.99/1.50 1.81/1.41 2.76/1.88 2.59/1.80 2.28/1.64
Multiplicative 1.92/1.38 1.84/.1.36 1.71/1.31 2.33/1.53 2.23/1.49 2.01/1.42
Recessive 1.50/– 1.47/– 1.40/– 1.69/– 1.65/– 1.55/–

*GRRs needed to achieve power of 0.80 and 0.95 when testing for association of the three‐locus RUNX1 and RAPTOR haplotypes are essentially identical to the GRRs of their constituent SNPs.

†For each locus, power was tested for the allele listed in table 1.

‡Power of 0.80 or 0.95 is not attainable. For both single SNPs and the three‐locus haplotype, power at a GRR2 ( = GRR1) of 2 and 5 is 0.18 and 0.42 for the TDT, 0.22 and 0.47 for the PDT, and 0.24 and 0.52 for the FBAT.

GRR1, genotype relative risk for test allele heterozygotes; GRR2, genotype relative risk for test allele homozygotes